Search Results
Your search for c matches 3694 pages
Showing 101 - 150Births and Adverse Obstetric Outcomes Among Female Survivors of Adolescent and Young Adult Cancers
In a population-based retrospective cohort study (Teenage and Young Adult Cancer Survivor Study; TYACSS) reported in The Lancet Oncology, Sunguc et al identified risks of adverse obstetric outcomes among female survivors of adolescent and young adult cancers in England and Wales. Study Details The...
Investigating Fungal Bloodstream Infections in Bone Marrow Transplant Recipients
Researchers may have uncovered the mechanisms behind fungal bloodstream infections in patients who receive bone marrow transplants, according to a recent study published by Zhai et al in Nature Medicine. Background A phenomenon known as heteroresistance occurs when a tiny fraction of bacteria...
Extranodal Marginal Zone Lymphoma: Is Overtreatment Common?
Most patients with extranodal marginal zone lymphoma (MZL) are overtreated, according to Emanuele Zucca, MD, of the Oncology Institute of Southern Switzerland and Institute of Oncology Research in Bellinzona and the Università della Svizzera Italiana in Lugano. “Aggressive therapy is not needed in...
Glofitamab Combination Therapy Shows Survival Benefit in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A novel treatment regimen with the bispecific antibody glofitamab has demonstrated improvements in survival outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to data presented at the European Hematology Association (EHA) 2024 Congress.1 The phase III ...
Education Level, Social Media Awareness May Be Linked to Cancer Fatalism
Investigators have found that patients with a lower level of education and social media awareness may hold more fatalistic beliefs about cancer compared with those who are more skilled at finding information through social media, according to a recent study published by Stimpson et al in Cancer...
Update on Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) Trial in Patients With Breast Cancer
Guest Editor’s Note: Chemotherapy and its side effects can lead to decreased physical activity and poor diet quality, resulting in unfavorable changes in physical functioning and quality of life. However, adopting healthy behaviors during cancer treatments can be challenging because of physical,...
Localized Hepatocellular Carcinoma
This is Part 3 of Immunotherapy Strategies for Hepatobiliary Cancers, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Rachna T. Shroff, Nilo Azad, and Anthony B. El-Khoueiry discuss the management of localized hepatocellular...
Updated ASCO Guidance on Cancer-Related Fatigue Expands Patient Options for Interventions
A new update to the ASCO guideline on managing cancer-related fatigue recommends that health care providers urge their patients to exercise, as well as use cognitive-behavioral therapy and mindfulness-based programs to help prevent and treat this prevalent symptom.1 It is estimated that between 30% ...
Two Phase III Trials Report Benefit With Isatuximab-Based Regimens in Newly Diagnosed Multiple Myeloma
In newly diagnosed, transplant-ineligible patients with multiple myeloma, treatment with the anti-CD38 monoclonal antibody isatuximab plus bortezomib, lenalidomide, and dexamethasone (VRd) led to a 40% reduction in the risk of disease progression or death and “deep and sustained responses,” almost...
AACR, ASA, FDA Outline Considerations for Overall Survival Analyses in Clinical Trials
Experts from the American Association for Cancer Research (AACR), American Statistical Association (ASA), and U.S. Food and Drug Administration (FDA) have outlined considerations for clinical trial designs to enhance the collection and analysis of overall survival data in the context of modern-day...
Response-Adapted Radiation Therapy for Orbital Indolent B-Cell Lymphoma
In a single-institution phase II trial reported in JAMA Oncology, Pinnix et al found that response-adapted radiation therapy featuring ultra–low-dose radiation therapy was a successful strategy in patients with indolent B-cell lymphoma of the ocular adnexa. As stated by the investigators:...
How Does Endometriosis Typology Influence Ovarian Cancer Risk?
In a Utah population–based cohort study reported in JAMA Network Open, Barnard et al found that women with ovarian endometriomas and/or deep-infiltrating endometriosis had a markedly increased risk of developing ovarian cancer. Those with such severe subtypes may represent an important population...
Long-Term Survival Possible After Liver Transplant for Colorectal Liver Metastases
In selected patients with unresectable colorectal liver metastases, liver transplantation plus chemotherapy significantly boosted overall survival as compared with chemotherapy alone in the multicenter, European TRANSMET trial, presented at the 2024 ASCO Annual Meeting.1 The combined approach led...
High-Risk Melanoma: Inhibiting MEK and PD-L1 in Tandem
Cobimetinib and atezolizumab administered prior to surgery eliminated or shrunk tumors in 70% of patients with melanoma enrolled in the NeoACTIVATE trial. Results were published by Hieken et al in Nature Communications. Background Melanoma of the skin is the fifth most common cancer type in the...
40% of Cancer Cases and Almost Half of All Cancer Deaths in the United States Linked to Modifiable Risk Factors
A recent study led by researchers at the American Cancer Society has found that 4 in 10 cancer cases and about half of all cancer deaths in adults aged 30 and older in the United States (or 713,340 cancer cases and 262,120 cancer deaths in 2019) may be attributed to modifiable risk factors,...
Predictive Models for Disease Recurrence After Breast-Conserving Surgery for DCIS
In a Canadian study reported in the Journal of Clinical Oncology, Hahn et al evaluated the impact of certain predictive models for local and invasive local recurrence in patients undergoing breast-conserving surgery with or without adjuvant radiotherapy for pure ductal carcinoma in situ (DCIS)....
Chronic Graft-vs-Host Disease: Clinical Trial Updates
Chronic graft-vs-host disease, an immune-mediated disorder that follows allogeneic hematopoietic cell transplantation (allo-HCT), is characterized by debilitating tissue injury with inflammatory and fibrotic pathology leading to significant morbidity and mortality. Historically, the treatment of...
ASCO Issues New Guidance on Vaccinations for Adults With Cancer
A new ASCO Clinical Practice Guideline recommends several vaccinations (eg, seasonal, herpes zoster, human papillomavirus [HPV], and others) for adults with solid or hematologic malignancies because of heightened infection risks from vaccine-preventable illnesses.1 The guideline covers the...
Risk of Adverse Obstetric Outcomes in Adolescent and Young Adult Cancer Survivors
In an English and Welsh study (The Teenage and Young Adult Cancer Survivor Study) reported in The Lancet Oncology, Sunguc et al found that cervical cancer and leukemia survivors have a heightened risk of experiencing several serious obstetric complications. “Therefore, any pregnancy [in these...
RELATIVITY-048: Triplet Immunotherapy Shows Activity in Untreated Advanced Melanoma
As a first-line treatment of advanced melanoma, the triplet immunotherapy regimen of nivolumab, relatlimab-rmbw, and ipilimumab produced high response rates and promising progression-free and overall survival in the nonrandomized phase I/II RELATIVITY-048 trial, as reported by Paolo Antonio...
Ciara C. O’Sullivan, MD, MBBCh, on HER2-Positive Breast Cancer: Expert Commentary on Treatments Under Study
Ciara C. O’Sullivan, MD, MBBCh, of Mayo Clinic, discusses three studies of treatment for patients with HER2-positive metastatic breast cancer and their clinical implications: the EMERALD trial of eribulin and taxane; the Patricia Cohort C trial of palbociclib plus trastuzumab and endocrine therapy; ...
Advanced Lung Cancer: Studies Explore Palliative Care Delivered by Telehealth and in a Stepped-Care Approach
Early palliative care can be integrated into the course of treatment for patients with advanced lung cancer via delivery by telehealth with outcomes similar to when palliative care is delivered via in-person visits, according to results of the REACH PC trial presented by Joseph Greer, PhD, of...
Oral SERDs Poised to Impact Treatment of Hormone Receptor–Positive Breast Cancer
Suppression of the estrogen receptor has proven to be an effective treatment for hormone receptor–positive breast cancer, but standard endocrine therapies have liabilities that are not limited to their pharmacokinetics or toxicity profiles, which allow for ligand-independent estrogen receptor...
FDA’s Oncology Center of Excellence Launches Project 5 in 5, a Crowdsourcing Initiative
OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, the OCE’s Steven Cunningham, MD, MLA, FACS, Clinical Reviewer on the Gastrointestinal Cancers Team,...
LEAP-001: Study Misses Endpoints but Still Shows Benefit for Lenvatinib/Pembrolizumab in Endometrial Cancer Subsets
The highly anticipated ENGOT-en9/LEAP-001 trial in endometrial cancer has missed both its primary endpoints. At the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer, the study investigators reported no significant benefit in progression-free survival or overall survival...
Optimizing the Management of DCIS
“Ductal carcinoma in situ (DCIS), once a rare entity, now comprises 20% to 30% of newly diagnosed breast cancers detected on mammography and is appreciated to be a widely heterogeneous disease,” said E. Shelley Hwang, MD, MPH, the Mary and Deryl Hart Distinguished Professor at Duke University, who ...
Prostate Cancer: Adjuvant Radiotherapy With 6 Months of ADT vs No ADT
In a component of the phase III RADICALS-HD trial reported in The Lancet, Chris C. Parker, MD, and colleagues found that metastasis-free survival was not significantly improved with 6 months of androgen-deprivation therapy (ADT) vs no ADT together with adjuvant radiotherapy in patients with...
Yasmin H. Karimi, MD, on Diffuse Large B-Cell Lymphoma: Update on Use of Epcoritamab Plus Chemotherapy
Yasmin H. Karimi, MD, of the University of Michigan Comprehensive Cancer Center, discusses data reaffirming the efficacy and feasibility of using epcoritamab plus R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin or carboplatin) in autologous stem cell transplant–eligible patients...
Neoadjuvant Immunotherapy Combination Improves Outcomes in Patients With Melanoma
Neoadjuvant immunotherapy given for stage III melanoma—followed by adjuvant therapy only if there is not a deep response to treatment—may produce better outcomes for patients than the current standard of care, which is adjuvant immunotherapy alone. These results from the NADINA trial were presented ...
Advanced Ovarian Cancer: Can Lymphadenectomy Be Avoided for Some Patients?
Some people with advanced epithelial ovarian cancer may safely avoid having their lymph nodes removed during surgery without it impacting their survival outcomes, helping to reduce the risk of postoperative complications. This research was presented by Classe et al at the 2024 ASCO Annual Meeting...
Ana C. Garrido-Castro, MD, on Managing Metastatic Breast Cancer in 2024
Ana C. Garrido-Castro, MD, of Dana-Farber Cancer Institute, discusses recent approvals of multiple novel therapies for metastatic breast cancer, weighing their potential benefits and risks, understanding the mechanisms that drive response and resistance, and exploring how to optimally sequence them ...
Ana C. Garrido-Castro, MD, on Metastatic Breast Cancer: Trial Update on Sacituzumab Govitecan With or Without Pembrolizumab
Ana C. Garrido-Castro, MD, of Dana-Farber Cancer Institute, reports the results from the phase II SACI-IO trial in patients with hormone receptor–positive/HER2-negative metastatic breast cancer who received sacituzumab govitecan-hziy with or without pembrolizumab (LBA1004).
Katherine C. Fuh, MD, PhD, on Ovarian Cancer: New Data on Batiraxcept and Paclitaxel
Katherine C. Fuh, MD, PhD, of the University of California, San Francisco, discusses phase III findings of the AXLerate-OC trial, showing that batiraxcept with paclitaxel compared to paclitaxel alone improved progression-free and overall survival in patients with platinum-resistant recurrent...
FDA’s Crowdsourcing Initiative to Benefit Patient-Centric Clinical Trial Innovation
The U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence (OCE) recently announced a new initiative called “Project 5 in 5.” Project 5 in 5 is a crowdsourcing initiative to ultimately identify five clinically relevant questions that can be answered through use of pragmatic...
Innovative Staging System for De Novo Metastatic Breast Cancer Validated Internationally
A ground breaking staging system for de novo metastatic breast cancer has been validated in an international cohort, perhaps paving the way for more personalized care and improved outcomes for patients diagnosed with this challenging disease. The staging system, developed by surgical oncologist...
ASCO Issues Updated Guidelines for Stage IV NSCLC With and Without Driver Alterations
ASCO has issued new evidence-based updates to two living guidelines on the treatment of stage IV NSCLC with and without driver alterations.1,2 Updated Recommendations: Stage IV NSCLC With Driver Alterations The most “extensive work” in the updates occurred in the guideline on stage IV NSCLC with...
Rosai-Dorfman Disease: Sinus Histiocytosis With Massive Lymphadenopathy
“Don’t be afraid to give up the good to go for the great.” — John D. Rockefeller The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, explore the ...
Is a Test for Early Detection of Pancreatic Cancer on the Horizon?
An investigational noninvasive exosome-based liquid biopsy shows potential for early detection of pancreatic cancer, an important unmet need, according to research presented at the American Association for Cancer Research (AACR) Annual Meeting 2024.1 When combined with the biomarker CA 19-9, the...
Apply Through July 31, 2024, for Survivorship Champion’s Prize
Children’s Cancer Cause, a national advocacy group in pioneering research and innovation for pediatric cancer, announced it is accepting applications for the Survivorship Champion’s Prize. This award is presented to a group, program, or institution that has demonstrated significant advancements in...
Novel Approaches Show Early Activity in Endocrine-Resistant Breast Cancer
For breast cancer that is estrogen receptor–positive, CDK4/6 inhibitors, given with endocrine therapy, have become the standard of care, especially in metastatic disease. However, resistance to both endocrine therapies and CDK4/6 inhibitors is common, and new approaches are needed to counteract...
Multiple Myeloma: Is MRD Status at 1 Year After Treatment Predictive of Survival?
Results from the Prognostic Immunophenotyping in Myeloma Response (PRIMeR) study, reported in the Journal of Clinical Oncology by Marcelo C. Pasquini, MD, MS, and colleagues, found that undetectable measurable residual disease (MRD) status at 1 year after autologous hematopoietic cell...
Cell-Free DNA Blood-Based Test and Next-Generation Multitarget Stool DNA Test in Colorectal Cancer Screening
In two studies reported in The New England Journal of Medicine, investigators found that a cell-free DNA (cfDNA) blood-based test (ECLIPSE study)1 and a next-generation multitarget stool DNA test (BLUE-C study)2 both showed high sensitivity for colorectal cancer and high specificity for advanced...
KEYNOTE-756 Additional Findings: Pembrolizumab Shown to Be Beneficial Regardless of Age, Menopausal Status
In updated findings from the phase III KEYNOTE-756 trial, the addition of pembrolizumab to chemotherapy in the neoadjuvant setting improved the rates of pathologic complete response for patients with high-risk estrogen receptor–positive, HER2-negative breast cancer, regardless of their age or...
AI in Cancer Care: Embrace the Change
According to Google Chief Executive Officer Sunder Pichai, artificial intelligence (AI) is “the most profound technology humanity is working on—more profound than fire or electricity or anything that we’ve done in the past.” The impact of AI on health care and especially cancer care will not be...
ASCO Survey Finds Oncologists’ Well-Being Worsened Over the Past Decade—but Steps Can Be Taken to Mitigate Burnout
A recent survey by ASCO measuring postpandemic burnout among oncologists in the United States shows that professional satisfaction and work-life balance have significantly deteriorated over the past decade, with 59% of respondents reporting one or more symptoms of burnout, compared with 34% in...
Bavituximab Plus Pembrolizumab for Patients With Hepatocellular Carcinoma
Adding the phosphatidylserine-targeting antibody bavituximab to the immunotherapy agent pembrolizumab may improve response rates without compromising safety in patients with hepatocellular carcinoma, according to a recent study published by Hsieh et al in Nature Communications. The findings...
Comparative Effectiveness of Acupuncture vs Massage for Relieving Pain in Patients With Advanced Cancer
Pain, a debilitating consequence of cancer and its treatments, is highly prevalent among patients with advanced cancer.1 Often persistent and undertreated, it is associated with poor functional and emotional well-being and typically occurs along with insomnia and fatigue.2 The use of opioids,...
Radon Gas Exposure May Be Linked to Increased Incidence of Lung Cancer in Nonsmokers
Long-term exposure to radon gas may be associated with a rise in nonsmoking lung cancer cases, according to a recent consumer survey conducted on behalf of The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James)....
Educational Videos May Encourage Prostate Cancer Screening Among Black Patients
Use of culturally sensitive educational videos may boost knowledge and decrease uncertainty regarding prostate cancer and screening among Black individuals, according to new findings presented by Jones et al at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract...
ATM Kinase Inhibitor Plus Radiotherapy for Patients With Glioblastoma
AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor, demonstrated a manageable safety profile in patients with both recurrent and newly diagnosed glioblastoma when given in combination with standard-of-care radiotherapy and showed preliminary efficacy in patients with recurrent...
